Ubiquigent Obtains Exclusive License for UbiSite Technology to Strengthen its Specialist Drug Discovery Services
Dundee, UK, 31 October 2022: Ubiquigent Limited (Ubiquigent), a
drug discovery and development company harnessing novel deubiquitylase
(DUB) modulators as new therapeutics for areas of high unmet medical
need, has signed an exclusive license with the University of Southern
Denmark for its UbiSite® technology. UbiSite will form a new component
in Ubiquigent’s DUB and ubiquitin-proteasome system (UPS) focused drug
discovery platform, providing a fully supported ubiquitomics service to
facilitate target identification, target validation, and compound
mechanism of action.
More info >> |